To determine whether ACH has meaningful or significant anti-obesity or anti-diabetic effects, further research, including pharmacokinetic and pharmacological studies, in vivo experiments under physiological conditions, and potentially human clinical trials, is necessary. The gene discussed is FGFR3; the disease is Obesity.